This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sachelarie, I. Articles by Blum, R. H. Search for Related Content PubMed PubMed Citation Articles by Sachelarie, I. Articles by Blum, R. H.

Breast Cancer

Primary Systemic Therapy of Breast Cancer

St. Luke’s-Roosevelt Medical Center, Beth Israel Medical Center, Continuum Cancer Center of New York, New York, New York, USA

Key Words. Primary systemic therapy • Pathologic complete response • Anthracycline • Taxane

Correspondence: Michael L. Grossbard, M.D., St. Luke’s-Roosevelt Medical Center, 11G, 1000 10th Avenue, New York, New York 10019, USA. Telephone: 212-523-5419; Fax: 212-523-2004; e-mail: mgrossbard{at}chpnet.org

Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing the rate of breast-conserving surgery and predicting outcome to a particular chemotherapy regimen, are also not conclusively established. We examined the published literature on PST for breast cancer and predominantly focused our review on data from large, randomized clinical trials comparing primary systemic chemotherapy with adjuvant chemotherapy, different primary systemic chemotherapy regimens, primary systemic chemotherapy with hormonal therapy, and different preoperative hormonal therapies. Although the optimal neoadjuvant chemotherapy regimen has not been established, a combination of four cycles of an anthracycline followed by four cycles of a taxane appears to produce the highest pCR rate (22%–31%). In patients with HER-2-positive breast cancer, concurrent use of neoadjuvant trastuzumab with an anthracycline–taxane combination has produced provocative results that require further confirmatory studies. Preoperative hormonal therapy is associated with low pCR rates and should be reserved for patients who are poor candidates for systemic chemotherapy. The optimal management of patients with residual disease after the administration of maximum neoadjuvant therapy remains to be defined. The surgical approach, including the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients, is evolving. Ongoing clinical trials will help identify the subset of patients who would most benefit from the use of PST, establish the most effective PST regimen, and determine the optimal multidisciplinary approach in the management of breast cancer.

This article has been cited by other articles:

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al. Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer Anticancer Res, February 1, 2009; 29(2): 517 - 524. [Abstract] [Full Text] [PDF]

				A.-M. Tokes, A. M. Szasz, A. Farkas, A. I. Toth, M. Dank, L. Harsanyi, B. A. Molnar, I. A. Molnar, Z. Laszlo, Z. Rusz, et al. Stromal Matrix Protein Expression Following Preoperative Systemic Therapy in Breast Cancer Clin. Cancer Res., January 15, 2009; 15(2): 731 - 739. [Abstract] [Full Text] [PDF]

				A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions Oncologist, November 1, 2008; 13(11): 1137 - 1148. [Abstract] [Full Text] [PDF]

				C. Liedtke, C. Mazouni, K. R. Hess, F. Andre, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1275 - 1281. [Abstract] [Full Text] [PDF]

				L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409. [Abstract] [Full Text] [PDF]

				O Camara, M Rengsberger, A Egbe, A Koch, M Gajda, U Hammer, C Jorke, C Rabenstein, M Untch, and K Pachmann The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer Ann. Onc., September 1, 2007; 18(9): 1484 - 1492. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]